Skip to main content
Journal cover image

884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer

Publication ,  Conference
Colombo, N; Antill, Y; Barretina Ginesta, MP; Harano, K; Hudson, E; Marmé, F; Marth, C; Rabaglio, M; Secord, AA; Fossati, R; Roberto, A ...
Published in: Annals of Oncology
September 2020

Duke Scholars

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

September 2020

Volume

31

Start / End Page

S647 / S647

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Colombo, N., Antill, Y., Barretina Ginesta, M. P., Harano, K., Hudson, E., Marmé, F., … Biagioli, E. (2020). 884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. In Annals of Oncology (Vol. 31, pp. S647–S647). Elsevier BV. https://doi.org/10.1016/j.annonc.2020.08.2090
Colombo, N., Y. Antill, M. P. Barretina Ginesta, K. Harano, E. Hudson, F. Marmé, C. Marth, et al. “884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.” In Annals of Oncology, 31:S647–S647. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.2090.
Colombo N, Antill Y, Barretina Ginesta MP, Harano K, Hudson E, Marmé F, et al. 884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. In: Annals of Oncology. Elsevier BV; 2020. p. S647–S647.
Colombo, N., et al. “884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.” Annals of Oncology, vol. 31, Elsevier BV, 2020, pp. S647–S647. Crossref, doi:10.1016/j.annonc.2020.08.2090.
Colombo N, Antill Y, Barretina Ginesta MP, Harano K, Hudson E, Marmé F, Marth C, Rabaglio M, Secord AA, Fossati R, Roberto A, Tettamanzi F, Biagioli E. 884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. Annals of Oncology. Elsevier BV; 2020. p. S647–S647.
Journal cover image

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

September 2020

Volume

31

Start / End Page

S647 / S647

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis